Halozyme Therapeutics (HALO) PT Set at $27.00 by Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald set a $27.00 price objective on Halozyme Therapeutics (NASDAQ:HALO) in a research report report published on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

HALO has been the subject of a number of other reports. ValuEngine upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating in a research report on Wednesday, October 3rd. BidaskClub cut shares of Halozyme Therapeutics from a buy rating to a hold rating in a research report on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a research report on Wednesday, July 11th. Piper Jaffray Companies started coverage on shares of Halozyme Therapeutics in a research report on Thursday, October 18th. They issued a hold rating and a $17.00 target price for the company. Finally, BMO Capital Markets increased their target price on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a market perform rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $20.78.

Shares of NASDAQ HALO opened at $15.80 on Tuesday. The stock has a market capitalization of $2.31 billion, a PE ratio of 35.11 and a beta of 1.88. The company has a quick ratio of 3.43, a current ratio of 3.49 and a debt-to-equity ratio of 0.31. Halozyme Therapeutics has a 52 week low of $14.33 and a 52 week high of $21.48.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. The business had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $30.42 million. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. The company’s quarterly revenue was down 59.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.02 earnings per share. As a group, equities research analysts predict that Halozyme Therapeutics will post -0.81 EPS for the current fiscal year.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 490,072 shares of the stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $17.30, for a total transaction of $8,478,245.60. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at $61,629,312.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Randal J. Kirk sold 161,246 shares of the stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $17.15, for a total transaction of $2,765,368.90. Following the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at approximately $61,094,954.20. The disclosure for this sale can be found here. Insiders sold 3,366,750 shares of company stock valued at $59,188,579 in the last three months. 14.10% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in HALO. Cambridge Investment Research Advisors Inc. purchased a new position in Halozyme Therapeutics during the third quarter worth about $205,000. Raymond James & Associates purchased a new position in Halozyme Therapeutics during the second quarter worth about $222,000. Amalgamated Bank boosted its stake in Halozyme Therapeutics by 19.3% during the second quarter. Amalgamated Bank now owns 19,053 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 3,077 shares during the period. Fox Run Management L.L.C. purchased a new position in Halozyme Therapeutics during the third quarter worth about $326,000. Finally, Xact Kapitalforvaltning AB boosted its stake in Halozyme Therapeutics by 26.1% during the first quarter. Xact Kapitalforvaltning AB now owns 18,369 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 3,800 shares during the period. 84.63% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Recommended Story: What is a Reverse Stock Split?

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply